---
title: "MindMaze Taps Vibra Partnership to Scale U.S. Neurorehab Platform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286041032.md"
description: "MindMaze Therapeutics has partnered with Vibra Healthcare to expand its FDA-cleared digital neurorehabilitation platform across U.S. health systems. This strategic partnership builds on a previous rollout in five rehabilitation facilities, demonstrating the ability to deliver high-dose therapy without increasing staff. The collaboration aims to enhance patient care and outcomes while MindMaze anticipates increased customer acquisition starting in late 2026. MindMaze develops precision neurotherapeutics for conditions like stroke and Parkinson's, utilizing advanced technology to support patient recovery."
datetime: "2026-05-12T05:45:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286041032.md)
  - [en](https://longbridge.com/en/news/286041032.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286041032.md)
---

# MindMaze Taps Vibra Partnership to Scale U.S. Neurorehab Platform

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from RELIEF THERAPEUTICS Holding ( (CH:MMTX) ).

MindMaze Therapeutics has entered a definitive channel partnership agreement with Vibra Healthcare to expand deployment of its FDA-cleared digital neurorehabilitation platform across leading U.S. health systems. Vibra, a major post-acute care provider with a network of specialty hospitals and rehabilitation centers, will act as MindMaze Therapeutics’ strategic commercial partner in the U.S.

The agreement builds on Vibra’s two-year, multi-site rollout of the MindMaze Therapeutics platform in five inpatient rehabilitation facilities, which showed that high-dose, high-intensity therapy can be delivered at scale without adding staff. By leveraging Vibra’s national relationships, the partnership aims to help providers treat more patients at higher levels of care with existing resources and improve outcomes such as shorter inpatient stays and better community discharge rates, with MindMaze Therapeutics expecting a boost in U.S. customer acquisition from the second half of 2026 onward.

**More about RELIEF THERAPEUTICS Holding**

MindMaze Therapeutics, listed on the SIX Swiss Exchange, develops scalable precision neurotherapeutics that combine advanced software, proprietary sensors, and AI-driven analytics to support recovery for neurological patients from hospital to home-based care. Its FDA-cleared and CE-marked digital platforms target stroke, Parkinson’s disease, and other neurological disorders, aiming to address clinician shortages with reimbursable, clinically validated solutions.

**Average Trading Volume:** 724,809

**Technical Sentiment Signal:** Sell

**Current Market Cap:** CHF58.31M

See more data about MMTX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [RLFTF.US](https://longbridge.com/en/quote/RLFTF.US.md)

## Related News & Research

- [MindMaze sharpens U.S. neurotherapeutics push after NeuroX–Relief merger and 2025 report](https://longbridge.com/en/news/282788092.md)
- [ZAWYA: Thumbay Group breaks ground on the region's first private, fully integrated psychiatric and rehabilitation hospital](https://longbridge.com/en/news/286411610.md)
- [ZAWYA: Thumbay Group breaks ground on the region's first private, fully integrated psychiatric and rehabilitation hospital](https://longbridge.com/en/news/286224300.md)
- [ZAWYA: Family Care Authority inaugurates service sentre and Halfway Homes project in Al Dhafra region](https://longbridge.com/en/news/286286795.md)
- [Sofis Partners with Arcadea Group](https://longbridge.com/en/news/286380775.md)